

# Christopher J Pepper

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8906164/publications.pdf>

Version: 2024-02-01

137  
papers

4,155  
citations

117453

34  
h-index

118652

62  
g-index

137  
all docs

137  
docs citations

137  
times ranked

6132  
citing authors

#	ARTICLE	IF	CITATIONS
1	A genome-wide association study identifies six susceptibility loci for chronic lymphocytic leukemia. <i>Nature Genetics</i> , 2008, 40, 1204-1210.	9.4	329
2	Common variants at 2q37.3, 8q24.21, 15q21.3 and 16q24.1 influence chronic lymphocytic leukemia risk. <i>Nature Genetics</i> , 2010, 42, 132-136.	9.4	223
3	Mcl-1 expression has in vitro and in vivo significance in chronic lymphocytic leukemia and is associated with other poor prognostic markers. <i>Blood</i> , 2008, 112, 3807-3817.	0.6	208
4	A genome-wide association study identifies multiple susceptibility loci for chronic lymphocytic leukemia. <i>Nature Genetics</i> , 2014, 46, 56-60.	9.4	166
5	CD49d Is the Strongest Flow Cytometry-Based Predictor of Overall Survival in Chronic Lymphocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2014, 32, 897-904.	0.8	162
6	Telomere dysfunction and fusion during the progression of chronic lymphocytic leukemia: evidence for a telomere crisis. <i>Blood</i> , 2010, 116, 1899-1907.	0.6	148
7	The NF- $\kappa$ B subunit Rel A is associated with in vitro survival and clinical disease progression in chronic lymphocytic leukemia and represents a promising therapeutic target. <i>Blood</i> , 2008, 111, 4681-4689.	0.6	145
8	Expansion of a CD8+PD-1+ Replicative Senescence Phenotype in Early Stage CLL Patients Is Associated with Inverted CD4:CD8 Ratios and Disease Progression. <i>Clinical Cancer Research</i> , 2012, 18, 678-687.	3.2	127
9	REGULATION OF CLINICAL CHEMORESISTANCE BY bcl-2 AND BAX ONCOPROTEINS IN B-CELL CHRONIC LYMPHOCYTIC LEUKAEMIA. <i>British Journal of Haematology</i> , 1996, 95, 513-517.	1.2	112
10	Substituted 4-(Thiazol-5-yl)-2-(phenylamino)pyrimidines Are Highly Active CDK9 Inhibitors: Synthesis, X-ray Crystal Structures, Structure-Activity Relationship, and Anticancer Activities. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 640-659.	2.9	111
11	Elevated Bcl-2/Bax Are a Consistent Feature of Apoptosis Resistance in B-cell Chronic Lymphocytic Leukaemia and Are Correlated with <i>In Vivo</i> Chemoresistance. <i>Leukemia and Lymphoma</i> , 1998, 28, 355-361.	0.6	100
12	The vitamin D3 analog EB1089 induces apoptosis via a p53-independent mechanism involving p38 MAP kinase activation and suppression of ERK activity in B-cell chronic lymphocytic leukemia cells in vitro. <i>Blood</i> , 2003, 101, 2454-2459.	0.6	89
13	Interaction with Vascular Endothelium Enhances Survival in Primary Chronic Lymphocytic Leukemia Cells via NF- $\kappa$ B Activation and <i>De novo</i> Gene Transcription. <i>Cancer Research</i> , 2010, 70, 7523-7533.	0.4	88
14	The role of Bcl-2 family proteins in chronic lymphocytic leukaemia. <i>Leukemia Research</i> , 2010, 34, 837-842.	0.4	84
15	The effect of immunoglobulinVH gene mutation status and other prognostic factors on the incidence of major infections in patients with chronic lymphocytic leukemia. <i>Cancer</i> , 2006, 107, 1023-1033.	2.0	82
16	Genome-wide association analysis implicates dysregulation of immunity genes in chronic lymphocytic leukaemia. <i>Nature Communications</i> , 2017, 8, 14175.	5.8	75
17	Antisense-mediated suppression of Bcl-2 highlights its pivotal role in failed apoptosis in B-cell chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 1999, 107, 611-615.	1.2	73
18	Telomere dysfunction accurately predicts clinical outcome in chronic lymphocytic leukaemia, even in patients with early stage disease. <i>British Journal of Haematology</i> , 2014, 167, 214-223.	1.2	73

#	ARTICLE	IF	CITATIONS
19	A novel Cdk9 inhibitor preferentially targets tumor cells and synergizes with fludarabine. <i>Oncotarget</i> , 2014, 5, 375-385.	0.8	73
20	Common Polymorphism G(-248)A in the Promoter Region of the bax Gene Results in Significantly Shorter Survival in Patients With Chronic Lymphocytic Leukemia Once Treatment Is Initiated. <i>Journal of Clinical Oncology</i> , 2005, 23, 1514-1521.	0.8	69
21	Blinatumomab induces autologous T-cell killing of chronic lymphocytic leukemia cells. <i>Haematologica</i> , 2013, 98, 1930-1938.	1.7	64
22	CD49d is an independent prognostic marker that is associated with CXCR4 expression in CLL. <i>Leukemia Research</i> , 2011, 35, 750-756.	0.4	60
23	CDK1-71, a novel CDK9 inhibitor, is preferentially cytotoxic to cancer cells compared to flavopiridol. <i>International Journal of Cancer</i> , 2012, 130, 1216-1226.	2.3	54
24	Flavopiridol circumvents Bcl-2 family mediated inhibition of apoptosis and drug resistance in B-cell chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2001, 114, 70-77.	1.2	53
25	Rel A Is an Independent Biomarker of Clinical Outcome in Chronic Lymphocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2009, 27, 763-769.	0.8	51
26	Telomere dysfunction and its role in haematological cancer. <i>British Journal of Haematology</i> , 2012, 156, 573-587.	1.2	51
27	Comparative Structural and Functional Studies of 4-(Thiazol-5-yl)-2-(phenylamino)pyrimidine-5-carbonitrile CDK9 Inhibitors Suggest the Basis for Isotype Selectivity. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 660-670.	2.9	51
28	GC-Targeted C8-Linked Pyrrolobenzodiazepine-Biaryl Conjugates with Femtomolar in Vitro Cytotoxicity and in Vivo Antitumor Activity in Mouse Models. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 2911-2935.	2.9	50
29	Inhibitory- $\hat{\nu}$ B Kinase (IKK) $\hat{\nu}$ and Nuclear Factor- $\hat{\nu}$ B (NF $\hat{\nu}$ B)-Inducing Kinase (NIK) as Anti-Cancer Drug Targets. <i>Cells</i> , 2018, 7, 176.	1.8	49
30	Targeting RNA transcription and translation in ovarian cancer cells with pharmacological inhibitor CDKI-73. <i>Oncotarget</i> , 2014, 5, 7691-7704.	0.8	48
31	Mimicking the tumour microenvironment: three different co-culture systems induce a similar phenotype but distinct proliferative signals in primary chronic lymphocytic leukaemia cells. <i>British Journal of Haematology</i> , 2012, 158, 589-599.	1.2	45
32	The Novel Nuclear Factor- $\hat{\nu}$ B Inhibitor LC-1 Is Equipotent in Poor Prognostic Subsets of Chronic Lymphocytic Leukemia and Shows Strong Synergy with Fludarabine. <i>Clinical Cancer Research</i> , 2008, 14, 8102-8111.	3.2	44
33	Defining the prognosis of early stage chronic lymphocytic leukaemia patients. <i>British Journal of Haematology</i> , 2012, 156, 499-507.	1.2	44
34	Genetic correlation between multiple myeloma and chronic lymphocytic leukaemia provides evidence for shared aetiology. <i>Blood Cancer Journal</i> , 2019, 9, 1.	2.8	40
35	Targeting CDK9 for treatment of colorectal cancer. <i>Molecular Oncology</i> , 2019, 13, 2178-2193.	2.1	39
36	The Hsp90 inhibitor NVP-AUY922-AG inhibits NF- $\hat{\nu}$ B signaling, overcomes microenvironmental cytoprotection and is highly synergistic with fludarabine in primary CLL cells. <i>Oncotarget</i> , 2012, 3, 525-534.	0.8	38

#	ARTICLE	IF	CITATIONS
37	Proteomics-Based Strategies To Identify Proteins Relevant to Chronic Lymphocytic Leukemia. <i>Journal of Proteome Research</i> , 2014, 13, 5051-5062.	1.8	33
38	CD49d promotes disease progression in chronic lymphocytic leukemia: new insights from CD49d bimodal expression. <i>Blood</i> , 2020, 135, 1244-1254.	0.6	33
39	Bcl-2 Antisense Oligonucleotides Enhance the Cytotoxicity of Chlorambucil in B-Cell Chronic Lymphocytic Leukaemia Cells. <i>Leukemia and Lymphoma</i> , 2001, 42, 491-498.	0.6	32
40	Activation of naïve CD4+ T cells re-tunes STAT1 signaling to deliver unique cytokine responses in memory CD4+ T cells. <i>Nature Immunology</i> , 2019, 20, 458-470.	7.0	32
41	NF- $\kappa$ B as a prognostic marker and therapeutic target in chronic lymphocytic leukemia. <i>Future Oncology</i> , 2009, 5, 1027-1037.	1.1	31
42	Development and characterization of a physiologically relevant model of lymphocyte migration in chronic lymphocytic leukemia. <i>Blood</i> , 2014, 123, 3607-3617.	0.6	31
43	Genome-wide association analysis of chronic lymphocytic leukaemia, Hodgkin lymphoma and multiple myeloma identifies pleiotropic risk loci. <i>Scientific Reports</i> , 2017, 7, 41071.	1.6	31
44	Flavopiridol Induces Apoptosis in B-cell Chronic Lymphocytic Leukaemia Cells Through a p38 and ERK MAP Kinase-dependent Mechanism. <i>Leukemia and Lymphoma</i> , 2003, 44, 337-342.	0.6	27
45	Phenotype and immune function of lymph node and peripheral blood CLL cells are linked to transendothelial migration. <i>Blood</i> , 2016, 128, 563-573.	0.6	27
46	The Novel Sequence-Specific DNA Cross-Linking Agent SJG-136 (NSC 694501) Has Potent and Selective In vitro Cytotoxicity in Human B-Cell Chronic Lymphocytic Leukemia Cells with Evidence of a p53-Independent Mechanism of Cell Kill. <i>Cancer Research</i> , 2004, 64, 6750-6755.	0.4	26
47	Telomere length is a critical determinant for survival in multiple myeloma. <i>British Journal of Haematology</i> , 2017, 178, 94-98.	1.2	26
48	The HSP90 inhibitor NVP-AUY922-AG inhibits the PI3K and IKK signalling pathways and synergizes with cytarabine in acute myeloid leukaemia cells. <i>British Journal of Haematology</i> , 2013, 161, 57-67.	1.2	25
49	Dissecting the role of the CXCL12/CXCR4 axis in acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2020, 189, 815-825.	1.2	23
50	TP53 Mutations with Low Variant Allele Frequency Predict Short Survival in Chronic Lymphocytic Leukemia. <i>Clinical Cancer Research</i> , 2021, 27, 5566-5575.	3.2	23
51	Transcriptomics-Based Characterization of the Toxicity of ZnO Nanoparticles Against Chronic Myeloid Leukemia Cells. <i>International Journal of Nanomedicine</i> , 2020, Volume 15, 7901-7921.	3.3	22
52	Leukemic and Non-Leukemic Lymphocytes from Patients with Li Fraumeni Syndrome Demonstrate Loss of p53 Function, Bcl-2 Family Dysregulation and Intrinsic Resistance to Conventional Chemotherapeutic Drugs But Not Flavopiridol. <i>Cell Cycle</i> , 2003, 2, 52-57.	1.3	21
53	Telomere length is an independent prognostic marker in MDS but not in de novo AML. <i>British Journal of Haematology</i> , 2017, 178, 240-249.	1.2	21
54	Racemisation of drug enantiomers by benzylic proton abstraction at physiological pH. <i>Chirality</i> , 1994, 6, 400-404.	1.3	20

#	ARTICLE	IF	CITATIONS
55	Understanding cancer cell survival is key to patient survival. <i>Lancet Oncology</i> , 2015, 16, 122-124.	5.1	20
56	TLR9 expression in chronic lymphocytic leukemia identifies a promigratory subpopulation and novel therapeutic target. <i>Blood</i> , 2021, 137, 3064-3078.	0.6	20
57	Increased frequency of CD4 <sup>+</sup> PD-1 <sup>+</sup> HLA-DR <sup>+</sup> T cells is associated with disease progression in CLL. <i>British Journal of Haematology</i> , 2020, 188, 872-880.	1.2	18
58	Acute renal failure as the presenting feature of leukaemic infiltration in chronic lymphocytic leukaemia. <i>Clinical and Experimental Nephrology</i> , 2009, 13, 179-181.	0.7	17
59	Pharmacological Importance of Simple Phenolic Compounds on Inflammation, Cell Proliferation and Apoptosis with a Special Reference to Î²-D-Salicin and Hydroxybenzoic Acid. <i>European Journal of Inflammation</i> , 2013, 11, 327-336.	0.2	17
60	Small-Molecule Inhibitors of 25-Hydroxyvitamin D-24-Hydroxylase (CYP24A1): Synthesis and Biological Evaluation. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 7702-7715.	2.9	17
61	Effects of Systematic Shortening of Noncovalent C8 Side Chain on the Cytotoxicity and NF-Î²B Inhibitory Capacity of Pyrrolbenzodiazepines (PBDs). <i>Journal of Medicinal Chemistry</i> , 2019, 62, 2127-2139.	2.9	17
62	Key Molecular Drivers of Chronic Lymphocytic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 593-606.	0.2	15
63	A laboratory-based scoring system predicts early treatment in Rai 0 chronic lymphocytic leukemia. <i>Haematologica</i> , 2020, 105, 1613-1620.	1.7	15
64	Cytomegalovirus infection does not impact on survival or time to first treatment in patients with chronic lymphocytic leukemia. <i>American Journal of Hematology</i> , 2016, 91, 776-781.	2.0	14
65	Tumor cell migration is inhibited by a novel therapeutic strategy antagonizing the alpha-7 receptor. <i>Oncotarget</i> , 2017, 8, 11414-11424.	0.8	14
66	Retinoid-induced apoptosis in B-cell chronic lymphocytic leukaemia cells is mediated through caspase-3 activation and is independent of p53, the retinoic acid receptor, and differentiation. <i>European Journal of Haematology</i> , 2002, 69, 227-235.	1.1	13
67	Telomere length predicts for outcome to FCR chemotherapy in CLL. <i>Leukemia</i> , 2019, 33, 1953-1963.	3.3	12
68	Structure-based design of highly selective 2,4,5-trisubstituted pyrimidine CDK9 inhibitors as anti-cancer agents. <i>European Journal of Medicinal Chemistry</i> , 2021, 214, 113244.	2.6	10
69	Single Diastereomers of the Clinical Anticancer ProTide Agents NUC-1031 and NUC-3373 Preferentially Target Cancer Stem Cells <i>In Vitro</i> . <i>Journal of Medicinal Chemistry</i> , 2021, 64, 8179-8193.	2.9	10
70	Lymph Node Derived CLL Cells Have a More Activated Phenotype and Better Antigen Presentation Capabilities Compared To Those From The Peripheral Blood. <i>Blood</i> , 2013, 122, 4119-4119.	0.6	10
71	Telomere fusions associate with coding sequence and copy number alterations in CLL. <i>Leukemia</i> , 2019, 33, 2093-2097.	3.3	9
72	Genome-wide association study identifies risk loci for progressive chronic lymphocytic leukemia. <i>Nature Communications</i> , 2021, 12, 665.	5.8	9

#	ARTICLE	IF	CITATIONS
73	Apoptosis Deregulation in CLL. <i>Advances in Experimental Medicine and Biology</i> , 2013, 792, 151-171.	0.8	8
74	Leukemic and non-leukemic lymphocytes from patients with Li Fraumeni syndrome demonstrate loss of p53 function, Bcl-2 family dysregulation and intrinsic resistance to conventional chemotherapeutic drugs but not flavopiridol. <i>Cell Cycle</i> , 2003, 2, 53-8.	1.3	8
75	Antisense Oligonucleotides Complementary to Bax Transcripts Reduce the Susceptibility of B-cell Chronic Lymphocytic Leukaemia Cells to Apoptosis in a Bcl-2 Independent Manner. <i>Leukemia and Lymphoma</i> , 2002, 43, 2003-2009.	0.6	7
76	A CD21 low phenotype, with no evidence of autoantibodies to complement proteins, is consistent with a poor prognosis in CLL. <i>Oncotarget</i> , 2015, 6, 32669-32680.	0.8	6
77	Elucidation of Focal Adhesion Kinase as a Modulator of Migration and Invasion and as a Potential Therapeutic Target in Chronic Lymphocytic Leukemia. <i>Cancers</i> , 2022, 14, 1600.	1.7	6
78	Targeting the Non-Canonical NF- $\kappa$ B Pathway in Chronic Lymphocytic Leukemia and Multiple Myeloma. <i>Cancers</i> , 2022, 14, 1489.	1.7	6
79	Enantioselectivity of aromatase inhibitors: Substituted 3-(4-aminophenyl)pyrrolidine-2,5-diones. <i>Chirality</i> , 1995, 7, 376-380.	1.3	5
80	Abstract 1129: GC-t8-linked pyrrolobenzodiazepine (PBD)-biaryl conjugates with femptomolar <i>in vitro</i> cytotoxicity and <i>in vivo</i> antitumour activity in mouse models of pancreatic and breast cancer.. <i>Cancer Research</i> , 2013, 73, 1129-1129.	0.4	5
81	NF Kappa B as a Therapeutic Target in AML. <i>Blood</i> , 2006, 108, 2587-2587.	0.6	5
82	Telomere analysis to predict chronic lymphocytic leukemia outcome: a STELA test to change clinical practice?. <i>Expert Review of Hematology</i> , 2014, 7, 701-703.	1.0	4
83	Clinical utility of telomere length measurements in cancer. <i>Current Opinion in Genetics and Development</i> , 2020, 60, 107-111.	1.5	4
84	Novel pyrrolobenzodiazepine benzofused hybrid molecules inhibit NF- $\kappa$ B activity and synergise with bortezomib and ibrutinib in hematological cancers. <i>Haematologica</i> , 2021, 106, 958-967.	1.7	4
85	Combined analysis of IGHV mutations, telomere length and CD49d identifies long-term progression-free survivors in TP53 wild-type CLL treated with FCR-based therapies. <i>Leukemia</i> , 2022, 36, 271-274.	3.3	4
86	PARP inhibition prevents escape from a telomere-driven crisis and inhibits cell immortalisation. <i>Oncotarget</i> , 2018, 9, 37549-37563.	0.8	4
87	IgM multiple myeloma: a diagnostic challenge in a patient with coexisting chronic lymphocytic leukaemia. <i>International Journal of Hematology</i> , 2008, 88, 424-427.	0.7	2
88	The Effect of Hydroxybenzoate Lithium Complexes in Inducing Apoptosis in HT-1080 Human Fibrosarcoma Cells. <i>Journal of Cancer Research</i> , 2013, 2013, 1-8.	0.7	2
89	Micro-Array and Protein Analyses Reveal a Preferential Autocrine VEGF Survival Loop in CD38+ Sub-Clones When Compared with CD38 <sup>+</sup> Sub-Clones Derived from the Same CLL Patient.. <i>Blood</i> , 2005, 106, 180-180.	0.6	2
90	The Aurora Kinase Inhibitor AZD1152 Causes Perturbation of Cell Cycle Distribution in Cell Lines and Primary AML Samples.. <i>Blood</i> , 2005, 106, 2759-2759.	0.6	2

#	ARTICLE	IF	CITATIONS
91	CD49d Is The Strongest Flow Cytometry-Based Predictor Of Overall Survival In Chronic Lymphocytic Leukemia. <i>Blood</i> , 2013, 122, 672-672.	0.6	2
92	The effect of hydroxybenzoate calcium compounds in inducing cell death in epithelial breast cancer cells. <i>Advances in Modern Oncology Research</i> , 2015, 1, .	0.1	2
93	<sc>CD</sc>8<sup>+</sup> Tâ€cell recognition of a synthetic epitope formed by <i>t</i>â€butyl modification. <i>Immunology</i> , 2015, 144, 495-505.	2.0	1
94	Proteomics-based identification of cancer-associated proteins in chronic lymphocytic leukaemia. <i>Electronic Journal of Biotechnology</i> , 2021, 52, 1-12.	1.2	1
95	Abstract 1874: MDX-124, a novel annexin-A1 antibody, induces an anti-tumor immune response and wide-ranging anti-cancer activity in multiple preclinical models. , 2021, , .		1
96	Multicentre Genome Wide Association Study Identifies Risk Alleles for Progressive Chronic Lymphocytic Leukaemia. <i>Blood</i> , 2019, 134, 1740-1740.	0.6	1
97	Prognostic Relevance of CD49d Expression On B Leukemic Cells in Chronic Lymphocytic Leukemia. Meta-Analysis of Published and unpublished Individual Data From 3146 Patients. <i>Blood</i> , 2012, 120, 3871-3871.	0.6	1
98	In Vitro Co-Culture of CLL-B Cells Reveals Long-Term Survival, Proliferation, and Maintenance of Telomere Length. <i>Blood</i> , 2016, 128, 350-350.	0.6	1
99	Longâ€term followâ€up of 415 patients with chronic lymphocytic leukemia treated with fludarabine and cyclophosphamideâ€based chemoimmunotherapy in the frontline <sc>ADMIRE</sc> and <sc>ARCTIC</sc> trials: A comprehensive assessment of prognostic factors. <i>American Journal of Hematology</i> , 2022, 97, .	2.0	1
100	Abstract 9: Effect of C8-side chain on the cytotoxicity and NF-kB inhibitory capacity of pyrrolobenzodiazepines. , 2019, , .		1
101	Interview: â€Familialâ€™ chronic lymphocytic leukemia. <i>International Journal of Hematologic Oncology</i> , 2012, 1, 27-28.	0.7	0
102	An Assessment of Calcium Handling and Cardiovascular Drug-Profiling in Cytiva Embryonic Stem-Cell Derived Cardiomyocytes. <i>Biophysical Journal</i> , 2013, 104, 604a.	0.2	0
103	Is venetoclax a new wonder drug in <sc>CLL</sc>?. <i>British Journal of Haematology</i> , 2019, 185, 643-646.	1.2	0
104	ZAP-70 Expression Is More Predictive Than VH Gene Mutational Status of BCR-Mediated Tyrosine Phosphorylation, NF-ÎB Activation and CLL Cell Survival.. <i>Blood</i> , 2005, 106, 2942-2942.	0.6	0
105	The Novel Anti-Leukemic Agent LC-1, Is Preferentially Cytotoxic in CLL Cells Derived from Poor Prognostic Subsets.. <i>Blood</i> , 2005, 106, 2981-2981.	0.6	0
106	Constitutive Nuclear p65 NF-kB Expression Predicts for Spontaneous Apoptosis and In Vitro Sensitivity to Fludarabine in CLL Cells.. <i>Blood</i> , 2006, 108, 4974-4974.	0.6	0
107	Inhibition of Cellular Aminopeptidases as Novel Therapy for AML.. <i>Blood</i> , 2006, 108, 2588-2588.	0.6	0
108	Integrating Prognostic Markers and Cellular Signaling Identifies More Chronic Lymphocytic Leukemia Patients with Adverse Prognosis.. <i>Blood</i> , 2006, 108, 2782-2782.	0.6	0

#	ARTICLE	IF	CITATIONS
109	The Sequence-Selective DNA Cross-Linking Agent SJG-136 (SG2000, BN2629) Is Highly Potent in Multiple Myeloma Cells and Is Synergistic with Bortezomib. Blood, 2008, 112, 5166-5166.	0.6	0
110	The DNA Crosslinking Agent SJG-136 (SG2000, BN2629) Is Highly Potent in Acute Myeloid Leukaemia and Is Synergistic with Cytarabine. Blood, 2008, 112, 4013-4013.	0.6	0
111	Pharmacological Inhibition of NF-KB Underpins the Strong Synergy Between LC-1 and Fludarabine in Chronic Lymphocytic Leukaemia Cells. Blood, 2008, 112, 380-380.	0.6	0
112	Rel a Is a Novel Prognostic Marker in CLL That Is Independent of VH Gene Mutation Status, CD38 Expression and ZAP-70 Expression. Blood, 2008, 112, 4153-4153.	0.6	0
113	The Parthenolide Derivative LC-1 Is An Effective Single Agent and Is Highly Synergistic with Existing Therapies in Multiple Myeloma.. Blood, 2008, 112, 1708-1708.	0.6	0
114	Topoisomerase II Inhibitor Voreloxin Causes Cell Cycle Arrest and Apoptosis in Acute Myeloid Leukaemia Cells and Acts in Synergy with Cytarabine.. Blood, 2009, 114, 4152-4152.	0.6	0
115	The Cyclin Dependent Kinase 2, 7 and 9 Inhibitor SNS-032 Has Single Agent Activity in Acute Myeloid Leukaemia Cells and Is Highly Synergistic with Cytarabine.. Blood, 2009, 114, 1059-1059.	0.6	0
116	CD38 Regulates Homing and Engraftment of CLL Cells,. Blood, 2011, 118, 3873-3873.	0.6	0
117	Abstract 1348: CD38 regulates homing and engraftment in a mouse model of CLL. , 2012, , .		0
118	Abstract 697: Synthesis and biological evaluation of 2,4,5-substituted pyrimidines as highly selective CDK9 inhibitors for cancer treatment.. , 2013, , .		0
119	Characterization Of a Novel In Vitro Circulation System Designed To Model The Migration Of Primary CLL Cells Across The Vascular Endothelium. Blood, 2013, 122, 667-667.	0.6	0
120	Longitudinal Analysis Reveals Telomere Length Maintenance In CLL B-Cells But Marked Erosion In CLL Patient T-Cells. Blood, 2013, 122, 1617-1617.	0.6	0
121	Abstract 1630: C8-linked pyrrolbenzodiazepine (pbd)-benzofused conjugates with low-picomolar in vitro cytotoxicity. , 2014, , .		0
122	CLL Is Associated with Development of Subclinical Cytomegalovirus Viraemia and Accumulation of Large Populations of â€œexhaustedâ€•CMV-Specific CD4+ T Cells. Blood, 2014, 124, 3290-3290.	0.6	0
123	CXCL12 Enhances CLL Cell and T-Cell Migration in a Dynamic Circulating Model of CLL That Can be Abrogated By the CXCR4 Antagonist ONO-7161. Blood, 2014, 124, 3293-3293.	0.6	0
124	Abstract 4555: C8-linked pyrrolbenzodiazepine (PBD)-benzofused hybrids as transcription factor inhibitors. , 2015, , .		0
125	Morphological modulation of human fibrosarcoma HT-1080 cells by hydroxybenzoate compounds during apoptosis. Advances in Modern Oncology Research, 2015, 1, 68.	0.1	0
126	Abstract LB-113: Antihormone-induced expression of BCL3 in estrogen receptor-positive breast cancer drives resistant cell growth. , 2016, , .		0



#	ARTICLE	IF	CITATIONS
127	Genetic Analysis of Distinct Phenotypic Subsets within MM1.S Multiple Myeloma Cell Line Reveals the Pre-Existence of MM.1R-like Glucocorticoid Resistance and a Sub-Clone with an Activating PI3-Kinase Delta Mutation That Is Preferentially Sensitive to the Selective PI3-Kinase Inhibitor, Idelalisib. <i>Blood</i> , 2016, 128, 4449-4449.	0.6	0
128	Chapter 5. Small Molecule Inhibitors of NF- $\kappa$ B and Their Therapeutic Potential in Leukaemia. <i>RSC Drug Discovery Series</i> , 2018, , 125-146.	0.2	0
129	Telomere Length Is Associated with Epigenetic Programming in CLL and Is a Superior Predictor of Clinical Outcome with the Ability to Bifurcate Patients with the Same CLL-IPI Score. <i>Blood</i> , 2018, 132, 1833-1833.	0.6	0
130	A Laboratory Based Scoring System Predicts Early Treatment in Rai 0/Binet a CLL. <i>Blood</i> , 2018, 132, 4399-4399.	0.6	0
131	Development and Characterisation of an in Vitro Model of Multiple Myeloma. <i>Blood</i> , 2018, 132, 4505-4505.	0.6	0
132	Telomere Length Predicts for Outcome to FCR Chemoimmunotherapy in CLL. <i>Blood</i> , 2018, 132, 1854-1854.	0.6	0
133	Hydroxybenzoate magnesium analogues induced apoptosis in HT-1080 human fibrosarcoma cells. <i>Clinical Sciences Research and Reports</i> , 2019, 2, .	0.2	0
134	Abstract 9: Effect of C8-side chain on the cytotoxicity and NF- $\kappa$ B inhibitory capacity of pyrrolbenzodiazepines. , 2019, , .		0
135	Telomere Length and CD49d Cooperate with IGHV Gene Status As Predictors of Long-Term Progression-Free Survival in CLL Patients Treated with FCR-Based Regimens. <i>Blood</i> , 2020, 136, 46-47.	0.6	0
136	Efficacy of MDX-124, a novel anti-annexin-A1 antibody, in preclinical models of pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 590-590.	0.8	0
137	Abstract P5-08-06: MDX-124, a novel annexin-A1 antibody, shows anti-tumor efficacy in several preclinical models of triple-negative breast cancer. <i>Cancer Research</i> , 2022, 82, P5-08-06-P5-08-06.	0.4	0